JAN 24, 2019 10:34 AM PST

Drug Blocks Toxic-Protein Production in ALS

WRITTEN BY: Nouran Amin

Individuals with ALS, frontotemporal dementia, carry a mutation in the gene C9orf72—resulting in repeated DNA sequences. These repetitions result in the production of toxic proteins that are associated with the development of ALS. Now, a new study aims to target a stress response with a known drug that may result in a decrease of toxic-protein production. "Both cellular stress and over-excitation eventually converge into the integrated stress response,” explains first author and graduate student, Thomas Westergard.

Learn more about ALS:

"Understanding what triggers toxic proteins production helped us hone in on drugs that could block them in laboratory tests," says co-senior author Aaron Haeusler, PhD, an Assistant Professor of Neuroscience within the Vickie & Jack Farber Institute for Neuroscience. Specifically, the researchers showed that the stress responses that trigger toxic protein production are similar to what happens during a seizure event.

The known drug used in the study is called ‘Trazodone’ and is currently approved for the treatment of depression and known to act on stress response. Trazodone was tested on models of the disease and was found to indeed inhibit toxic protein production of toxic protein in a cellular model contained the mutation. "This is a significant step forward in our collaborative approach," said co-author Dr. Piera Pasinelli, PhD, who lead the Jefferson Weinberg ALS Center. "Working together allowed us to speed up the research process getting from the identification of the "pathogenic stress" to testing a potentially useful drug. ALS is a complex and heterogenous disease that needs this collaborative approach, with each lab contributing its own expertise, to fill the gaps and to put together this complex puzzle in a systematic and efficient way.”

credit: healthiculture.com

Researchers are now looking forward to expand their studies for other compounds that might work better than trazodone. Results of the study were published in EMBO Molecular Medicine.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 13, 2019
Genetics & Genomics
NOV 13, 2019
DNA Construction Kit Could Drive Down Costs of Immune Therapy
Researchers at KU Leuven in Belgium have created a DNA construction kit that, when injected into muscle cells, enables sheep to produce new antibodies to f...
NOV 13, 2019
Cannabis Sciences
NOV 13, 2019
CBD Alleviates Angelman Syndrome Seizures in Mice Trial
CBD has already been shown to be effective as an anti-anxiety, antipsychotic and anti-epileptic substance. Can it help youth and adults with a rare neurolo...
NOV 13, 2019
Infographics
NOV 13, 2019
Surface Plasmon Resonance (SPR) Technology
Surface plasmon resonance (SPR) allows researchers to investigate different types of biomolecular interactions and mechanisms in real-time and label-free....
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Advancing Nanocontainers for Drug Delivery
Nanocontainers work by delivering drugs to a localized region in the body, many chemotherapeutics work in that matter. The high specificity of this drug de...
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Possible New Drug Targets for Glioblastoma
Scientists at Karolinska Institutet in Sweden were able to pinpoint 10 tumor-specific potential drug targets for the fatal and incurable brain cancer, glio...
NOV 13, 2019
Microbiology
NOV 13, 2019
The Mechanism of Lysostaphin, a MRSA-Killing Enzyme, is Revealed
This study can help inform the development of new treatments for antibiotic-resistant microbes....
Loading Comments...